271ce4d2-844f-4515-be45-10712b3685c5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- ANDROGEN_RESPONSE+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- ALLOGRAFT_REJECTION+0.200
- COMPLEMENT+0.200
- MITOTIC_SPINDLE+0.200
- PROTEIN_SECRETION+0.200
- APOPTOSIS+0.100
- BILE_ACID_METABOLISM+0.100
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- E2F_TARGETS-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- ADIPOGENESIS-0.200
- ANGIOGENESIS-0.200
- APICAL_SURFACE-0.200
- DNA_REPAIR-0.200
- MYC_TARGETS_V1-0.200
- ESTROGEN_RESPONSE_EARLY-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25043624 | — | — | 0.759 |
| 2 | 3a2b80a5-6937-423a-92bf-9e25a0b23c5b | — | — | 0.738 |
| 3 | 88340 | EPN | Supratentorial EPN | 0.731 |
| 4 | TCGA-EW-A1J5-01A-11R-A13Q-07 | — | B | 0.711 |
| 5 | SRR23303769 | — | — | 0.708 |
| 6 | TCGA-62-A46U-01A-11R-A24H-07 | — | cohortA1 | 0.704 |
| 7 | R134 | — | — | 0.700 |
| 8 | e598b2c1-abeb-4421-acf8-79fe3d507ef8 | — | — | 0.699 |
| 9 | GSM5359418 | — | — | 0.695 |
| 10 | 3e17c945-a810-4d82-af11-93debdee3f21 | — | — | 0.694 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |